Scotch Plains, NJ, United States of America

Richard John Varsolona

This inventor holds 25 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Boehringer Ingelheim International Gmbh. Active years: 1995-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard John Varsolona. Retrieved from https://idiyas.com/inventor/richard-john-varsolona

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 2)

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 5.1

ph-index = 5

Forward Citations = 92(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

5 out of 1,562

Boehringer Ingelheim International Gmbh

patents

4. 1 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

Areas of Expertise:

HIV Inhibitors

BACE Inhibitors

Finasteride Processes

Crystalline Forms

Macrolactams

Solid State Forms

Thermodynamically Stable Crystals

Growth Hormone Secretagogue

Tetracyclic Heterocycles

Thrombin Inhibitors

Pyrazole Compounds

Fluoroadenine

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12391694 - Process for the preparation of 2-fluoroadenine (2025-08-19),

2. 12018020 - Crystalline forms of 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide (2024-06-25),

3. 11542279 - Solid forms of ceftolozane and processes for preparing (2023-01-03),

4. 11306080 - Crystalline form of a BACE inhibitor, compositions, and use (2022-04-19),

5. 10457690 - Process for preparing substituted tetracyclic heterocycle compounds (2019-10-29),

6. 10017505 - Crystalline forms of a BACE inhibitor, compositions, and their use (2018-07-10),

7. 9873707 - Methods and intermediates for preparing macrolactams (2018-01-23),

8. 8598183 - Solid state forms of a potent HCV inhibitor (2013-12-03),

9. 8362035 - Crystalline forms of a potent HCV inhibitor (2013-01-29),

10. 8232293 - Crystalline forms of a potent HCV inhibitor (2012-07-31),

11. 7470795 - Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides (2008-12-30),

12. 7309700 - Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3′-e] [1,4]diazepin-6-one (2007-12-18),

13. 6642237 - Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides and uses thereof (2003-11-04),

14. 6486195 - Thermodynamically stable crystal form of 4″-deoxy-4″-epi-methylamino avermectin B1a/B1b benzoic acid salt and processes for its preparation (2002-11-26),

15. 6071916 - HIV protease inhibitor (2000-06-06),

Sure, I can help you with that. Let's start with the article about inventor Richard John Varsolona.

Title: The Innovative Legacy of Richard John Varsolona

Introduction:

Richard John Varsolona is a prolific inventor based in Scotch Plains, NJ (US) with an impressive track record in the field of pharmaceuticals. His dedication to innovation and research has led to the development of numerous groundbreaking patents.

Latest Patents:

Richard John Varsolona's latest patents showcase his expertise in the pharmaceutical industry. One of his innovations includes the development of a novel solid form of ceftolozane sulfate, offering new possibilities for drug synthesis and composition. Additionally, his work on a crystalline form of a BACE inhibitor shows promise in the treatment of Alzheimer's disease and related cognitive impairments.

Career Highlights:

Throughout his career, Richard John Varsolona has made significant contributions to companies like Merck & Company, Inc. and Boehringer Ingelheim International GmbH. His innovative spirit and commitment to scientific advancements have earned him recognition as a leading figure in the field of pharmaceutical research.

Collaborations:

In his professional journey, Richard John Varsolona has collaborated with esteemed colleagues such as David Askin and Paul J. Reider. Together, they have worked on cutting-edge projects that have pushed the boundaries of pharmaceutical innovation.

Conclusion:

In conclusion, Richard John Varsolona's impact on the world of pharmaceuticals cannot be understated. His groundbreaking patents and collaborations stand as a testament to his unwavering dedication to advancing science and improving healthcare outcomes. Richard John Varsolona's legacy as an inventor continues to inspire future generations of innovators in the field.

Profile summary based on public USPTO records.